• 1
    Lin JH 1996 Bisphosphonates: A review of their pharmacokinetic properties. Bone 18: 7585.
  • 2
    Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR 1993 Design of the Fracture Intervention Trial. Osteoporos Int 3(Suppl 3): S29S39.
  • 3
    World Health Organization 1994 Assessment of Osteoporotic Fracture Risk and Its Role in Screening for Postmenopausal Osteoporosis. WHO Technical Series, Geneva, Switzerland.
  • 4
    Genant HK, Jergas M 2003 Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int 14(Suppl 3): S43S55.
  • 5
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 11: 41184124.
  • 6
    Jamal SA, Bayoumi AM, Bauer DC, Cummings SR 2005 The clinical utility of laboratory testing in women with low bone mineral density. Osteoporos Int 16: 534540.
  • 7
    Cockcroft DW, Gault MH 1976 Prediction of creatinine clearance from serum creatinine. Nephron 16: 3141.
  • 8
    Froissart M, Rossert J, Jacquot C, Pillars M, Houillier P 2005 Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 16: 763773.
  • 9
    National Kidney Foundation 2002 K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1S266.
  • 10
    Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D 2000 Upper gastrointestinal tract safety profile of alendronate: The fracture intervention trial. Arch Intern Med 160: 517525.
  • 11
    Cummings SR, Bates D, Black DM 2002 Clinical use of bone densitometry: Scientific review. JAMA 288: 18891897.
  • 12
    Patel R, Blake GM, Rymer J, Fogelman I 2000 Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int 11: 6875.
  • 13
    Troehler U, Bonjour JP, Fleish H 1975 Renal secretion of diphosphonates in rats. Kidney Int 8: 613.
  • 14
    Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C 2000 Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58: 396399.
  • 15
    Coco M, Rush H 2000 Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 11151121.
  • 16
    Ensrud K, Lui L, Ishani A, Shlipak M, Taylor B, Antoniucci D, Stone K, Jamal SA, Homan M, Cummings SR 2005 Renal function and risk of hip and vertebral fractures among older women. J Bone Miner Res 20:S1; S380.
  • 17
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE 2005 Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res 20: 21052115.
  • 18
    Lindeman RD, Tobin J, Shock NW 1985 Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33: 278285.
  • 19
    Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P 2004 Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52: 18321839.
  • 20
    Klawansky S, Komaroff E, Cavanaugh PFJ, Mitchell DY, Gordon MJ, Connelly JE, Ross SD 2003 Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14: 570576.
  • 21
    National Kidney Foundation 2003 K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42(Suppl 3): S1S201.
  • 22
    Lewiecki EM, Rudolph LA 2003 Oral bisphosphonates for treatment of osteoporosis in elderly patients with impaired renal function. J Bone Miner Res 17:S1; S367.
  • 23
    Linnebur SA, Milchak JL 2004 Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function. Am J Geriatr Pharmacother 2: 213218.
  • 24
    Vervoort G, Willems HL, Wetzels FM 2002 Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: Validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 17: 19091913.